Norwegian University of Science and Technology
Trondheim, 7489, Norway
NCT Number: NCT00184444
The study investigates whether endurance training breathing 100% oxygen gives a additional improvement of maximal oxygen uptake in stable Angina Pectoris patients, compared to training without extra oxygen supplementation. In addition work economy, stroke volume and cardiac perfusion is measured.
The hypothesis of the study is that increased oxygenation of the air increases performance, stroke volume, work economy and cardiac perfusion.
Looking for future studies?
Notify Me18 year–75 year
All sexes
Interventional
Not applicable
Trondheim, 7489, Norway
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
4 x 4 minutes interval training in hypoxic air, 3 times per week at 90-95% HR max
4 x 4 minutes normoxic interval training, 3 times per week at 90-95% HR max
Time frame: Baseline and post training
Time frame: Baseline and post training
Time frame: Baseline and post training
Time frame: baseline and post training
Norwegian University of Science and Technology
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04175626
Acute Coronary Syndrome, Angina Pectoris
Fairhope, Alabama, United States
View Trial DetailsNCT04475380
Acute Coronary Syndrome, Angina Pectoris
Enschede, Netherlands
View Trial DetailsNCT05380063
Angina Pectoris, Arterial Occlusive Diseases
Beijing, China
View Trial DetailsNCT06181799
Angina Pectoris, Arterial Occlusive Diseases
Moscow, Russia
View Trial Details